Abbott Laboratories (ABT) stock
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3034% above fair value
$104.71−2.74 (-2.55%)
Close on Nov 17, 2026Market cap $181.19BP/E 33.7Yield 2.29%
Abbott Laboratories total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Abbott Laboratories's total debt was $32.61B at Jun 30, 2026. For fiscal 2025 it was $12.93B, down 8.5% from the year before. Over ten years it grew 3.7% a year on average. The highest annual figure on record is $27.92B in fiscal 2017.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.93B | -8.5% |
| FY2024 | Dec 31, 2024 | $14.13B | -3.8% |
| FY2023 | Dec 31, 2023 | $14.68B | -12.5% |
| FY2022 | Dec 31, 2022 | $16.77B | -7.1% |
| FY2021 | Dec 31, 2021 | $18.05B | -3.7% |
| FY2020 | Dec 31, 2020 | $18.75B | +3.4% |
| FY2019 | Dec 31, 2019 | $18.14B | -7.3% |
| FY2018 | Dec 31, 2018 | $19.57B | -29.9% |
| FY2017 | Dec 31, 2017 | $27.92B | +26.9% |
| FY2016 | Dec 31, 2016 | $22.01B | +144.5% |
| FY2015 | Dec 31, 2015 | $9.00B | +15.0% |
| FY2014 | Dec 31, 2014 | $7.83B | +19.3% |
| FY2013 | Dec 31, 2013 | $6.56B | -68.0% |
| FY2012 | Dec 31, 2012 | $20.48B | +32.8% |
| FY2011 | Dec 31, 2011 | $15.41B | -18.5% |
| FY2010 | Dec 31, 2010 | $18.92B | +15.0% |
| FY2009 | Dec 31, 2009 | $16.46B | +43.8% |
| FY2008 | Dec 31, 2008 | $11.45B | -6.3% |
| FY2007 | Dec 31, 2007 | $12.21B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $32.61B | +142.7% |
| Q1 FY2026 | Mar 31, 2026 | $34.05B | +157.1% |
| Q4 FY2025 | Dec 31, 2025 | $12.93B | -8.5% |
| Q3 FY2025 | Sep 30, 2025 | $12.94B | -13.6% |
| Q2 FY2025 | Jun 30, 2025 | $13.44B | -8.9% |
| Q1 FY2025 | Mar 31, 2025 | $13.24B | -9.2% |
| Q4 FY2024 | Dec 31, 2024 | $14.13B | -3.8% |
| Q3 FY2024 | Sep 30, 2024 | $14.98B | -3.5% |
| Q2 FY2024 | Jun 30, 2024 | $14.75B | -12.4% |
| Q1 FY2024 | Mar 31, 2024 | $14.59B | -13.7% |
| Q4 FY2023 | Dec 31, 2023 | $14.68B | -12.5% |
| Q3 FY2023 | Sep 30, 2023 | $15.53B | -5.4% |
| Q2 FY2023 | Jun 30, 2023 | $16.85B | +0.5% |
| Q1 FY2023 | Mar 31, 2023 | $16.90B | -1.1% |
| Q4 FY2022 | Dec 31, 2022 | $16.77B | -7.1% |
| Q3 FY2022 | Sep 30, 2022 | $16.41B | -10.8% |
| Q2 FY2022 | Jun 30, 2022 | $16.76B | -9.4% |
| Q1 FY2022 | Mar 31, 2022 | $17.09B | -7.3% |
| Q4 FY2021 | Dec 31, 2021 | $18.05B | -3.7% |
| Q3 FY2021 | Sep 30, 2021 | $18.40B | -0.9% |
| Q2 FY2021 | Jun 30, 2021 | $18.50B | -6.0% |
| Q1 FY2021 | Mar 31, 2021 | $18.44B | +0.9% |
| Q4 FY2020 | Dec 31, 2020 | $18.75B | +3.4% |
| Q3 FY2020 | Sep 30, 2020 | $18.56B | -2.8% |
| Q2 FY2020 | Jun 30, 2020 | $19.68B | +2.5% |
| Q1 FY2020 | Mar 31, 2020 | $18.27B | -4.1% |
| Q4 FY2019 | Dec 31, 2019 | $18.14B | -7.3% |
| Q3 FY2019 | Sep 30, 2019 | $19.10B | -18.9% |
| Q2 FY2019 | Jun 30, 2019 | $19.19B | -7.1% |
| Q1 FY2019 | Mar 31, 2019 | $19.05B | -13.0% |
| Q4 FY2018 | Dec 31, 2018 | $19.57B | -29.9% |
| Q3 FY2018 | Sep 30, 2018 | $23.56B | -1.9% |
| Q2 FY2018 | Jun 30, 2018 | $20.67B | -14.0% |
| Q1 FY2018 | Mar 31, 2018 | $21.89B | -8.7% |
| Q4 FY2017 | Dec 31, 2017 | $27.92B | +26.9% |
| Q3 FY2017 | Sep 30, 2017 | $24.03B | +182.3% |
| Q2 FY2017 | Jun 30, 2017 | $24.03B | – |
| Q1 FY2017 | Mar 31, 2017 | $23.97B | – |
| Q4 FY2016 | Dec 31, 2016 | $22.01B | – |
| Q3 FY2016 | Sep 30, 2016 | $8.51B | – |
See a number that looks wrong?